Swog Cancer Research Network

This study tests two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug works better at shrinking an enlarged spleen and reducing the need for blood transfusions. About 268 particip…

This study tests two drugs, alone or together, for people with advanced non-small cell lung cancer that has specific gene changes (like EGFR or ALK) and has come back after prior treatment. The drugs are sacituzumab govitecan, which delivers a toxin directly to cancer cells, and …

This study looks at whether adding focused treatments like surgery and radiation to standard drug therapy can help people with HER2-positive stage IV breast cancer that has spread to only a few spots. About 562 participants will either get standard drugs alone or drugs plus local…

This study tests whether adding a gut-health supplement (MO-03) to standard immunotherapy helps people with advanced or metastatic clear cell kidney cancer. About 718 participants will receive either MO-03 or a placebo alongside their regular treatment. The goal is to see if impr…

This study tests whether adding the targeted drug pirtobrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with Richter transformation, a fast-growing lymphoma that can develop from chronic lymphocytic leukemia. About 102 adults with this co…

This study is testing an educational program called A-PACT, which uses trained health coaches to help people with cancer have better conversations with their doctors about their treatment goals and end-of-life wishes. Over 1,000 patients will be randomly assigned to either receiv…